University of Illinois at Chicago

UIC clinical trials investigate COVID-19 treatments

Trials study Ebola, rheumatoid arthritis drugs in hospitalized patients

Newswise — The University of Illinois at Chicago is participating in two clinical trials for COVID-19 treatments.

COVID-19 is caused by a highly contagious virus called SARS-CoV-2 that results in acute lung injury and respiratory distress. There are currently no treatments for COVID-19.

In one trial, launched this week, a team from UIC is studying a drug previously approved by the U.S. Food and Drug Administration for treating rheumatoid arthritis. The drug is called sarilumab.

“Sarilumab targets cytokines, or small proteins, that are also seen in patients hospitalized with COVID-19,” said Dr. Jerry Krishnan, UIC professor of medicine and principal investigator of the study. 

The study includes investigators with expertise in pulmonary/critical care medicine, internal medicine, emergency medicine, pharmacy, nursing and human-centered design.

“This highly contagious virus carries unacceptably high morbidity and mortality because we do not have any evidence-based therapeutic options beyond supportive care — this study may change that,” Krishnan said. “Randomized clinical trials in which subjects are assigned to either receive the investigational treatment or an inactive treatment — called a placebo — are the gold standard to understanding the harms and benefits of new interventions.”

In the sarilumab study, hospitalized patients with COVID-19 who participate in the study will be randomized to one of three groups: sarilumab 200 mg, sarilumab 400 mg, or placebo, as a single IV infusion.

“Because of the life-threatening nature of COVID-19 among hospitalized patients, the study was designed to offer most study participants sarilumab; only 1 in 5 participants will be randomized to the placebo group,” Krishnan said.

Krishnan said the placebo group is needed to help us understand the harms and benefits of two doses of sarilumab compared with what would have happened without sarilumab.

The adaptive phase 2/phase 3 sarilumab study is sponsored by Regeneron Pharmaceuticals as part of a public-private partnership with the U.S. Department of Health and Human Services, the U.S. Office of the Assistant Secretary for Preparedness and Response, and the U.S. Biomedical Advanced Research and Development Authority.

In another trial, launched last week, UIC researchers are investigating an antiviral drug previously studied as a treatment for Ebola in hospitalized patients with COVID-19. The drug is called remdesivir and the trial is funded by the National Institutes of Health. 

In a news release, the NIH said remdesivir “has shown promise in animal models for treating Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), which are caused by other coronaviruses.”

UIC principal investigator and professor of medicine Dr. Richard Novak said, “We urgently need safe and effective treatments for COVID-19 and, through this trial, we hope to learn if remdesivir is beneficial for patients with COVID-19.

“It’s far too early to know if there will be a clinical benefit, but these kinds of trials are critical in the search for treatments.”

The remdesivir study is a phase 3 clinical trial, and UIC is one of 75 centers in the nation participating in the trial. 

For both studies, research participants will be enrolled through the University of Illinois Hospital.  

Filters close

Showing results

1120 of 3817
access_time Embargo lifts in 2 days
Embargo will expire: 17-Nov-2020 11:00 AM EST Released to reporters: 30-Oct-2020 9:40 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 17-Nov-2020 11:00 AM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: NEJM: Clinical Trial Indicates Monoclonal Antibody Lowered Hospitalizations and Emergency Visits
Released: 30-Oct-2020 8:25 AM EDT
NEJM: Clinical Trial Indicates Monoclonal Antibody Lowered Hospitalizations and Emergency Visits

COVID-19 (coronavirus) patients who were administered a novel antibody had fewer symptoms and were less likely to require hospitalization or emergency medical care than those who did not receive the antibody, according to a new study published in the The New England Journal of Medicine.

Newswise:Video Embedded newswise-expert-panels-on-covid-19-pandemic-notable-excerpts-quotes-and-videos-available
Released: 30-Oct-2020 8:25 AM EDT
Newswise Expert Panels on COVID-19 Pandemic: Notable excerpts, quotes and videos available

Newswise is hosting a series of Expert Panels discussion on unique aspects of the COVID-19 pandemic. This tip sheet includes some notable quotes from the panelists.

Newswise: Department of Energy’s Office of Technology Transitions providing funding for researchers to support COVID-19 projects
Released: 29-Oct-2020 6:45 PM EDT
Department of Energy’s Office of Technology Transitions providing funding for researchers to support COVID-19 projects
Argonne National Laboratory

The U.S. Department of Energy’s Office of Technology Transitions has announced a COVID-19 Technical Assistance Program that provides funding for national laboratory researchers to assist U.S. entities on COVID-19 projects.

Released: 29-Oct-2020 5:05 PM EDT
Chicago Parents More Worried Than U.S. Adults Overall About COVID-19
Ann and Robert H. Lurie Children's Hospital of Chicago

More than three in five Chicago parents (64 percent) were very concerned about COVID-19 affecting their family’s health, according to new survey results released by Ann & Robert H. Lurie Children’s Hospital of Chicago. Chicago parents were surveyed May – July, 2020. Their responses are in sharp contrast to the results from a national poll in July, which found that only 49 percent of U.S. adults were very worried about COVID-19 infecting them or someone in their family.

Released: 29-Oct-2020 4:05 PM EDT
UIC opens phase 3 monoclonal antibody clinical trial
University of Illinois at Chicago

Researchers at the University of Illinois Chicago are now enrolling people into a phase 3 clinical trial that will test if a monoclonal antibody treatment — administered as a series of four shots — will help protect uninfected individuals from acquiring or getting sick from COVID-19 after someone in the household tests positive for COVID-19.

Newswise: Models show how COVID-19 cuts a neighborhood path
Released: 29-Oct-2020 3:45 PM EDT
Models show how COVID-19 cuts a neighborhood path
University of Washington

A research team led by UC Irvine and the University of Washington has created a new model of how the coronavirus can spread through a community. The model factors in network exposure — whom one interacts with — and demographics to simulate at a more detailed level both where and how quickly the coronavirus could spread through Seattle and 18 other major cities.

Released: 29-Oct-2020 2:55 PM EDT
Lung scans for stroke patients could provide earlier COVID-19 detection
American Heart Association (AHA)

Computed tomography angiogram (CTA) scans may offer fast and early detection of COVID-19 in acute ischemic stroke (AIS) patients, according to new research published today in Stroke, a journal of the American Stroke Association, a division of the American Heart Association.

Newswise: How Does the Environment Impact COVID-19?
Released: 29-Oct-2020 2:10 PM EDT
How Does the Environment Impact COVID-19?
Homeland Security's Science And Technology Directorate

S&T NBACC research finds that sunlight is the strongest environmental factor that inactivates COVID-19.

Released: 29-Oct-2020 1:25 PM EDT
The Lancet Healthy Longevity: Residential context important factor in risk of COVID-19 mortality among older adults, Stockholm study suggests

New study of older adults (aged 70 or over) in Stockholm, Sweden, suggests older people living in care homes had higher COVID-19 mortality risk than those living in single houses or apartment buildings.

Showing results

1120 of 3817